As opposed to the P2a peer reviewed open label n=21 paper, the CTAD poster will likely conclude that the SIGMAR1 wt. vs. variant doesn't matter all that much. It will likely also state than S1R expression is elevated from baseline to EOT in the treatment "groups" (not arms according to Missing's answer in the latest CC) vs. placebo.
Market Data 
Markets 
AI
